Group 1 - The core viewpoint of the report is that Jingfeng Medical-B (02675) is rated as "Buy" with projected revenues of 4.32 billion, 8.11 billion, and 12.36 billion yuan for 2025-2027, respectively, and a target price of 73.20 yuan/79.57 HKD based on a 35X PS for 2026 [1] - Jingfeng Medical is a leader in the domestic surgical robot market, continuously innovating to drive technological advancements, having established a "three-in-one" surgical solution with multi-port, single-port, and natural orifice surgical robots [1] - The company has achieved significant milestones, being the first in China and the second globally to obtain regulatory approval for multiple types of surgical robots, with its MSP2000 system receiving CE certification in October 2025 [1] Group 2 - Since the commercialization of its multi-port surgical robot in December 2022, Jingfeng Medical has sold 20 units in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3 - In 2024, Jingfeng Medical successfully entered the overseas market, quickly securing 5 orders and establishing a global distribution network covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 units of core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Core Viewpoint - Cathay Securities initiates coverage on Precision Medical-B (02675) with a "Buy" rating, forecasting revenues of 432 million, 811 million, and 1.236 billion yuan for 2025-2027, respectively, and sets a target price of 73.20 yuan/79.57 HKD for 2026 based on a 35X PS ratio [1] Group 1: Company Overview - Precision Medical, founded in May 2017 in Shenzhen, is a leader in China's surgical robot sector, being the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - The company has developed a "three-in-one" surgical solution that includes multi-port, single-port, and remote systems, with its globally pioneering MSP2000 multi-port surgical robot system receiving CE certification in October 2025 [1] Group 2: Market Performance - Since the commercialization of its multi-port surgical robot in December 2022, Precision Medical sold 20 units in China in 2024, ranking first among domestic manufacturers, with clinical applications covering over 220 hospitals across 30 provinces [2] - The company's total revenue is projected to increase from 48 million yuan in 2023 to 160 million yuan in 2024, and from 30 million yuan in H1 2024 to 149 million yuan in H1 2025 [2] Group 3: International Expansion - In 2024, Precision Medical successfully entered the overseas market, securing 5 orders and establishing a global sales team covering five continents [3] - By H1 2025, the company had 30 distributors, including 10 overseas, and signed global sales agreements for 118 core products, with 72 units designated for international markets, marking a significant step in its globalization efforts [3]

Core Viewpoint - Shenzhen Jingfeng Medical Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange with an opening price of HKD 43.24 per share, achieving a market capitalization of HKD 23 billion on its first trading day, reflecting strong investor interest in the surgical robotics sector [3]. Company Overview - Jingfeng Medical specializes in advanced surgical robots, including multi-port and single-port laparoscopic surgical robots. The company received EU CE certification for its SP1000 and MSP2000 systems, marking a significant milestone as the first integrated surgical robot platform from China [5][11]. - The company was founded by alumni of Tianjin University, Wang Jianchen and Gao Yuanqian, and has attracted investments from notable firms such as Lenovo Star, Sequoia China, and Hillhouse Capital [5][11]. Investment Insights - Lenovo Star, the only early-stage investment firm with a systematic focus on healthcare, has seen a nearly 20-fold return on its investment of approximately HKD 28 million following Jingfeng Medical's successful IPO [5][12]. - The investment decision was based on a thorough analysis of the surgical robotics market, with a particular focus on the competitive landscape and the technical capabilities of Jingfeng Medical's team [10][14]. Market Potential - The laparoscopic surgical robot market is viewed as a critical battleground, with multi-port systems being essential for competitive positioning. The team behind Jingfeng Medical is recognized for its strong technical foundation and innovative capabilities [7][15]. - The company has expanded its clinical applications across 30 provinces in China, partnering with over 220 hospitals, including top-tier hospitals and grassroots healthcare facilities [11]. Technological Advancements - Jingfeng Medical's "Jingfeng Cloud" system aims to overcome geographical limitations in surgical capabilities, achieving over 500 surgeries globally and setting a Guinness World Record for the longest-distance surgery [11][18]. - The company is also focusing on enhancing AI capabilities in its surgical robots, with experimental validations indicating significant advancements in surgical efficiency and safety [18]. Strategic Positioning - Lenovo Star's investment strategy emphasizes the integration of AI and robotics in healthcare, aiming to identify and support innovative companies that can redefine industry standards [17][18]. - The firm has established a unique position by balancing investments in both technology and healthcare, allowing it to capitalize on emerging opportunities in the medical sector [16][17].